Compass Therapeutics Inc. (CMPX) has a current Price-to-Book (P/B) ratio of 4.38. Compared to its 3-year average P/B ratio of 2.26, the current P/B ratio is approximately 93.76% higher. Relative to its 5-year average P/B ratio of 3.13, the current P/B ratio is about 40.11% higher. Compass Therapeutics Inc. (CMPX) has a Forward Free Cash Flow (FCF) yield of approximately -4.90%. Compared to its 3-year average FCF yield of -15.59%, the current FCF yield is approximately -68.56% lower. Relative to its 5-year average FCF yield of -13.11%, the current FCF yield is about -62.60% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CMPX competitors is -28.95, providing a benchmark for relative valuation. Compass Therapeutics Inc. Corp (CMPX.O) exhibits a P/S ratio of -334.38, which is 1054.9% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CMPX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CMPX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CMPX currently overvalued or undervalued?

What is Compass Therapeutics Inc. (CMPX) fair value?

CMPX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Compass Therapeutics Inc. (CMPX) is between to according to relative valuation method.

How does CMPX's valuation metrics compare to the industry average?

The average P/S ratio for CMPX's competitors is -28.95, providing a benchmark for relative valuation. Compass Therapeutics Inc. Corp (CMPX) exhibits a P/S ratio of -334.38, which is 1054.90% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Compass Therapeutics Inc. (CMPX) as of Mar 03 2026?

As of Mar 03 2026, Compass Therapeutics Inc. (CMPX) has a P/B ratio of 4.38. This indicates that the market values CMPX at 4.38 times its book value.

What is the current FCF Yield for Compass Therapeutics Inc. (CMPX) as of Mar 03 2026?

As of Mar 03 2026, Compass Therapeutics Inc. (CMPX) has a FCF Yield of -4.90%. This means that for every dollar of Compass Therapeutics Inc.'s market capitalization, the company generates -4.90 cents in free cash flow.

What is the current Forward P/E ratio for Compass Therapeutics Inc. (CMPX) as of Mar 03 2026?

As of Mar 03 2026, Compass Therapeutics Inc. (CMPX) has a Forward P/E ratio of -12.21. This means the market is willing to pay $-12.21 for every dollar of Compass Therapeutics Inc.'s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Compass Therapeutics Inc. (CMPX) as of Mar 03 2026?

As of Mar 03 2026, Compass Therapeutics Inc. (CMPX) has a Forward P/S ratio of -334.38. This means the market is valuing CMPX at $-334.38 for every dollar of expected revenue over the next 12 months.

CMPX Valuation